IS8502A - Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar - Google Patents

Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar

Info

Publication number: IS8502A
Authority: IS; Iceland
Prior art keywords: sup; azate; receptor antagonists; cannabinoid receptor; formula
Prior art date: 2003-12-19

Application number

IS8502A

Other languages

English (en)

Icelandic (is)

Inventor

Yu Guixue

William R Ewing

Amarendra B Mikkilineni

Pendri Annapurna

Philip M Sher

Gerritz Samuel

Bruce A Ellsworth

Wu Gang

Huang Yanting

Sun Congqing

Murugesan Natesan

Gu Zhengxiang

Wang Ying

Sitkoff Doree

Stephen R Johnson

Wu Ximao

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-19

Filing date

2006-06-08

Publication date

2006-06-08

2006-06-08 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2006-06-08 Publication of IS8502A publication Critical patent/IS8502A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Immunology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Vascular Medicine (AREA)

IS8502A 2003-12-19 2006-06-08 Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar IS8502A (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US53145103P	2003-12-19	2003-12-19
PCT/US2004/042820 WO2005063761A1 (en)	2003-12-19	2004-12-17	Azabicyclic heterocycles as cannabinoid receptor modulators
US11/016,135 US7378418B2 (en)	2003-12-19	2004-12-17	Azabicyclic heterocycles as cannabinoid receptor modulators

Publications (1)

Publication Number	Publication Date
IS8502A true IS8502A (is)	2006-06-08

Family

ID=34703659

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8502A IS8502A (is)	2003-12-19	2006-06-08	Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar

Country Status (19)

Country	Link
US (1)	US7378418B2 (da)
EP (1)	EP1697370B1 (da)
JP (1)	JP2007514768A (da)
AT (1)	ATE360630T1 (da)
AU (1)	AU2004309365A1 (da)
BR (1)	BRPI0417771A (da)
CA (1)	CA2550435A1 (da)
CY (1)	CY1106674T1 (da)
DE (1)	DE602004006165T2 (da)
DK (1)	DK1697370T3 (da)
ES (1)	ES2282927T3 (da)
HR (1)	HRP20070241T3 (da)
IL (1)	IL176107A0 (da)
IS (1)	IS8502A (da)
NO (1)	NO20062704L (da)
PL (1)	PL1697370T3 (da)
PT (1)	PT1697370E (da)
RU (1)	RU2006126122A (da)
WO (1)	WO2005063761A1 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100210590A1 (en) *	1995-09-27	2010-08-19	Northwestern University	Compositions and treatments for seizure-related disorders
EP1430033A4 (en)	2001-08-31	2004-12-15	Univ Northwestern	ANTI-INFLAMMATORY AND PROTEIN-INK-INHIBITING COMPOSITION AND THEIR USE
CN1875021A (zh) *	2003-11-04	2006-12-06	默克公司	取代的萘啶酮衍生物
MX2007005247A (es)	2004-11-02	2008-03-13	Univ Northwestern	Compuestos de piridazina, composiciones y metodos.
ATE523199T1 (de) *	2004-11-02	2011-09-15	Univ Northwestern	Pyridazinverbindungen und verfahren
BRPI0609614A2 (pt) *	2005-04-04	2010-04-20	Univ Pontificia Catolica Chile	uso de ezetimiba na prevenção e tratamento de litìases de colesterol na árvore biliar
US7452892B2 (en) *	2005-06-17	2008-11-18	Bristol-Myers Squibb Company	Triazolopyrimidine cannabinoid receptor 1 antagonists
US7632837B2 (en)	2005-06-17	2009-12-15	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid-1 receptor modulators
US8022073B2 (en) *	2005-12-07	2011-09-20	Sumitomo Chemical Company, Limited	Substituted pyridazine compounds and fungicidal uses thereof
CA2632936A1 (en) *	2005-12-20	2007-06-28	Merck Frosst Canada Ltd.	Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2009528999A (ja) *	2006-02-21	2009-08-13	アンプラファーマシューティカルズインコーポレイテッド	Ｃｂ１アンタゴニストおよび逆アゴニスト
AU2007243280A1 (en)	2006-04-28	2007-11-08	Northwestern University	Formulations containing pyridazine compounds for treating neuroinflammatory diseases
US8158627B2 (en)	2006-04-28	2012-04-17	Northwestern University	Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
AR061637A1 (es) *	2006-06-26	2008-09-10	Epix Delaware Inc	Composiciones y metodos de tratamiento de trastornos del snc
JP2010500300A (ja)	2006-08-08	2010-01-07	サノフィ−アベンティス	アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2051696A2 (en) *	2006-08-18	2009-04-29	Morton Grove Pharmaceuticals, Inc.	Stable liquid levetiracetam compositions and methods
EP2368879B1 (en) *	2006-11-30	2012-11-21	Dow AgroSciences LLC	2,5-disubstituted pyridines for the preparation of 2-substituted 5-(1-alkylthio)-alkyl-pyridines
EP1974608A1 (de) *	2007-03-30	2008-10-01	Bayer CropScience AG	Arylpyridazine als Fungizide
US11241420B2 (en)	2007-04-11	2022-02-08	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
CN110403942A (zh)	2007-04-11	2019-11-05	奥默罗斯公司	预防和治疗成瘾的组合物和方法
US20160331729A9 (en)	2007-04-11	2016-11-17	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
JP5485148B2 (ja) *	2007-06-21	2014-05-07	カラセラピューティクスインコーポレイテッド	置換イミダゾ複素環
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2200997B9 (en)	2007-09-13	2016-01-13	Concert Pharmaceuticals Inc.	Synthesis of deuterated benzodioxoles
EP2042491A1 (de) *	2007-09-14	2009-04-01	Bayer CropScience AG	Pyridazine als Fungizide
GB2456183A (en)	2008-01-04	2009-07-08	Gw Pharma Ltd	Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
CN101590239B (zh) *	2008-05-30	2013-03-27	北京奥萨医药研究中心有限公司	含有利尿剂、他汀和叶酸的药物组合物及其用途
WO2010003624A2 (en)	2008-07-09	2010-01-14	Sanofi-Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
UY32045A (es) *	2008-08-12	2010-03-26	Takeda Pharmaceutical	Compuesto amida
US20100113583A1 (en) *	2008-10-16	2010-05-06	Aronne Louis J	Combination therapies for the treatment of obesity
US20100113603A1 (en) *	2008-10-16	2010-05-06	Aronne Louis J	Combination therapies for the treatment of obesity
WO2010045529A2 (en) *	2008-10-16	2010-04-22	Metabolous Pharmaceuticals, Inc.	Combination therapies for the treatment of obesity
WO2010045522A2 (en) *	2008-10-16	2010-04-22	Metabolous Pharmaceuticals, Inc.	Combination therapies for the treatment of obesity
WO2010045563A2 (en) *	2008-10-16	2010-04-22	Metabolous Pharmaceuticals, Inc.	Combination therapies for the treatment of obesity
WO2010151503A2 (en) *	2009-06-25	2010-12-29	Metabolous Pharmaceuticals, Inc.	Combination therapies for the treatment of obesity
WO2010151565A2 (en) *	2009-06-26	2010-12-29	Metabolous Pharmaceuticals, Inc.	Combination therapies for the treatment of obesity
WO2011008490A2 (en) *	2009-06-29	2011-01-20	Metabolous Pharmaceuticals, Inc.	Combination therapies for the treatment of obesity
US20110015663A1 (en) *	2009-07-17	2011-01-20	Aronne Louis J	Combination Therapies for the Treatment of Obesity
EP2483406A2 (en)	2009-09-30	2012-08-08	President and Fellows of Harvard College	Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
US20110082407A1 (en) *	2009-10-01	2011-04-07	Aronne Louis J	Combination Therapies for the Treatment of Obesity
TW201124078A (en)	2009-12-22	2011-07-16	Du Pont	Fungicidal 2-(bicyclic aryloxy) carboxamides
WO2011078360A1 (ja)	2009-12-24	2011-06-30	武田薬品工業株式会社	アミド化合物
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US20130197043A1 (en)	2010-08-31	2013-08-01	Snu R&Db Foundation	Use of the fetal reprogramming of a ppar agonist
US8993591B2 (en) *	2010-11-08	2015-03-31	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012087372A1 (en)	2010-12-22	2012-06-28	E. I. Du Pont De Nemours And Company	Fungicidal 2-(bicyclic aryloxy)carboxamides
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
JP5437525B1 (ja)	2012-12-28	2014-03-12	株式会社ナード研究所	チロシン誘導体およびチロシン誘導体の製造方法
EP3404115A1 (en)	2013-03-27	2018-11-21	F. Hoffmann-La Roche AG	Genetic markers for predicting responsiveness to therapy
MX384679B (es)	2014-07-30	2025-03-14	Hoffmann La Roche	Marcadores genéticos para predecir la reactividad a terapia con agente que eleva la lipoproteína de alta densidad (hdl) o que imita la lipoproteína de alta densidad (hdl).
US9585867B2 (en)	2015-08-06	2017-03-07	Charles Everett Ankner	Cannabinod formulation for the sedation of a human or animal
PE20190622A1 (es)	2016-06-02	2019-04-26	Abbvie Inc	Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
US11584744B2 (en) *	2017-06-23	2023-02-21	University Of Washington	Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them
EP3658172A4 (en)	2017-07-25	2021-05-05	TrueBinding, Inc.	TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
HUE054428T2 (hu)	2017-12-01	2021-09-28	Abbvie Inc	Glükokortikoid receptor agonista és annak immunkonjugátumai
JP7053900B2 (ja)	2018-06-15	2022-04-12	ファイザー・インク	Ｇｌｐ－１受容体アゴニストおよびその使用
WO2020087031A1 (en)	2018-10-26	2020-04-30	The Research Foundation For The State University Of New York	Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN120058944A (zh)	2019-01-30	2025-05-30	真和制药有限公司	抗gal3抗体及其用途
BR112021022682A2 (pt)	2019-05-14	2022-02-22	Provention Bio Inc	Métodos e composições para prevenir diabetes do tipo 1
MX2022014786A (es)	2020-05-26	2023-01-16	Truebinding Inc	Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CA3182445A1 (en)	2020-06-11	2021-12-16	Francisco Leon	Methods and compositions for preventing type 1 diabetes
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3994898A (en) *	1975-10-16	1976-11-30	E. R. Squibb & Sons, Inc.	1,2,4-Triazolo (4,3-b) pyridazin-3-ones
US4515791A (en) *	1980-06-03	1985-05-07	American Cyanamid Company	Substituted phenyl-1,2,4-triazolo[2,3-b]pyridazin-3(2H)ones as anti-asthma agents
JPS61106576A (ja) *	1984-10-31	1986-05-24	Nippon Soda Co Ltd	トリアゾロピリダジン−３−オン誘導体及び製造方法
US6610694B1 (en)	1998-10-06	2003-08-26	Takeda Chemical Industries, Ltd.	Condensed pyridazine compounds, their production and use
JP2002205992A (ja)	2000-11-08	2002-07-23	Takeda Chem Ind Ltd	二環式トリアゾロン誘導体およびそれを含有する除草剤
WO2004074259A1 (en)	2003-02-19	2004-09-02	Neurogen Corporation	Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds

2004
- 2004-12-17 CA CA002550435A patent/CA2550435A1/en not_active Abandoned
- 2004-12-17 PT PT04814952T patent/PT1697370E/pt unknown
- 2004-12-17 AU AU2004309365A patent/AU2004309365A1/en not_active Abandoned
- 2004-12-17 HR HR20070241T patent/HRP20070241T3/xx unknown
- 2004-12-17 ES ES04814952T patent/ES2282927T3/es not_active Expired - Lifetime
- 2004-12-17 US US11/016,135 patent/US7378418B2/en not_active Expired - Lifetime
- 2004-12-17 PL PL04814952T patent/PL1697370T3/pl unknown
- 2004-12-17 JP JP2006545558A patent/JP2007514768A/ja not_active Withdrawn
- 2004-12-17 BR BRPI0417771-1A patent/BRPI0417771A/pt not_active IP Right Cessation
- 2004-12-17 AT AT04814952T patent/ATE360630T1/de not_active IP Right Cessation
- 2004-12-17 DK DK04814952T patent/DK1697370T3/da active
- 2004-12-17 WO PCT/US2004/042820 patent/WO2005063761A1/en not_active Ceased
- 2004-12-17 DE DE602004006165T patent/DE602004006165T2/de not_active Expired - Fee Related
- 2004-12-17 RU RU2006126122/04A patent/RU2006126122A/ru not_active Application Discontinuation
- 2004-12-17 EP EP04814952A patent/EP1697370B1/en not_active Expired - Lifetime
2006
- 2006-06-04 IL IL176107A patent/IL176107A0/en unknown
- 2006-06-08 IS IS8502A patent/IS8502A/xx unknown
- 2006-06-12 NO NO20062704A patent/NO20062704L/no not_active Application Discontinuation
2007
- 2007-06-21 CY CY20071100832T patent/CY1106674T1/el unknown

Also Published As

Publication number	Publication date
US20050143381A1 (en)	2005-06-30
WO2005063761A1 (en)	2005-07-14
EP1697370A1 (en)	2006-09-06
RU2006126122A (ru)	2008-01-27
BRPI0417771A (pt)	2007-04-17
DE602004006165D1 (de)	2007-06-06
ATE360630T1 (de)	2007-05-15
HK1095139A1 (en)	2007-04-27
IL176107A0 (en)	2006-10-05
CA2550435A1 (en)	2005-07-14
HRP20070241T3 (hr)	2007-07-31
NO20062704L (no)	2006-09-05
US7378418B2 (en)	2008-05-27
DK1697370T3 (da)	2007-09-17
CY1106674T1 (el)	2012-05-23
AU2004309365A1 (en)	2005-07-14
JP2007514768A (ja)	2007-06-07
PT1697370E (pt)	2007-05-31
PL1697370T3 (pl)	2007-09-28
ES2282927T3 (es)	2007-10-16
EP1697370B1 (en)	2007-04-25
DE602004006165T2 (de)	2008-01-17

Publication	Publication Date	Title
IS8502A (is)	2006-06-08	Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
IS8503A (is)	2006-06-08	Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
TW200726765A (en)	2007-07-16	Triazolopyridine cannabinoid receptor 1 antagonists
NO20062689L (no)	2006-09-12	Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
SE0401345D0 (sv)	2004-05-25	Therapeutic compounds: Pyridine as scaffold
CY1107850T1 (el)	2013-06-19	Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
SE0401971D0 (sv)	2004-08-02	Piperidne derivatives
SE0302760D0 (sv)	2003-10-20	New compounds
SE0402762D0 (sv)	2004-11-11	Indazole sulphonamide derivatives
WO2006044362A3 (en)	2006-12-07	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
SE0401342D0 (sv)	2004-05-25	Therapeutic compounds
SE9900961D0 (sv)	1999-03-16	Novel compounds
SE0302573D0 (sv)	2003-09-26	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv)	2003-06-10	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0102055D0 (sv)	2001-06-08	New Compounds
SE0301699D0 (sv)	2003-06-10	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv)	2003-09-26	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE9902267D0 (sv)	1999-06-16	New compounds
SE0302572D0 (sv)	2003-09-26	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DE602005010744D1 (de)	2008-12-11	Piperazinylpyridinderivate als mittel gegen adipositas
SE0400285D0 (sv)	2004-02-10	Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
SE0402763D0 (sv)	2004-11-11	Nitro indazole derivatives
SE0401343D0 (sv)	2004-05-25	Therapeutic compounds: Pyridine N oxide as scaffold
SE0301698D0 (sv)	2003-06-10	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2006076598A3 (en)	2006-08-24	Bicyclic heterocycles as cannabinoid receptor modulators